← Back to Browse
Ask AleraHome
MRI
AbdomenDemonstration data

MRI Abdomen with Contrast

Contrast-enhanced abdominal MRI provides superior soft-tissue contrast and multiphase characterization of hepatic, pancreatic, biliary, renal, and adrenal pathology without ionizing radiation. Chemical-shift imaging, diffusion, and dynamic gadolinium phases enable lesion detection and specific characterization such as fat, fibrosis, and vascularity. MRCP non-invasively depicts the biliary and pancreatic ducts. It is the problem-solving tool of choice following equivocal ultrasound or CT.

Indications

  • Detection and characterization of focal liver lesions (hemangioma, FNH, adenoma, HCC, metastases)
  • Chronic liver disease surveillance and HCC characterization using hepatobiliary or extracellular agents
  • MRCP for choledocholithiasis, biliary strictures, and pancreatic ductal anatomy
  • Characterization of pancreatic masses, cystic lesions, and pancreatitis complications
  • Indeterminate renal masses and characterization of complex cysts
  • Adrenal lesion characterization (adenoma vs non-adenoma) via chemical-shift imaging
  • Assessment of iron and fat content in diffuse liver disease
  • Problem-solving of indeterminate CT/ultrasound findings and staging of abdominal malignancy

Contraindications & Cautions

  • Non-MRI-conditional implanted devices and ferromagnetic foreign bodies
  • Severe renal impairment (eGFR <30) restricts gadolinium; use macrocyclic agents and weigh risk of nephrogenic systemic fibrosis
  • Gadolinium hypersensitivity
  • Pregnancy: avoid gadolinium; non-contrast MRI/MRCP is preferred when imaging is essential
  • Inability to breath-hold degrades dynamic imaging; consider free-breathing/radial techniques
  • Severe claustrophobia

Patient Preparation

  • MRI safety screening for devices and implants
  • Fast 4-6 hours to reduce bowel motion, empty the stomach, and improve MRCP by minimizing fluid overlap
  • Administer negative oral contrast (e.g., pineapple/blueberry juice) to suppress overlapping GI fluid for MRCP
  • Check eGFR and obtain contrast consent
  • Establish IV access for power injection of gadolinium
  • Coach breath-holding; consider antispasmodic to reduce bowel motion
  • Position supine with a body phased-array coil and respiratory monitoring

Technique & Parameters

  • 1.5T or 3T with body/torso phased-array coil and respiratory or navigator gating
  • Axial and coronal T2 (single-shot and fat-saturated) and axial in-/opposed-phase T1 (Dixon) for fat/iron
  • Diffusion-weighted imaging with ADC for lesion detection and characterization
  • MRCP: heavily T2-weighted thick-slab radial and 3D thin-section acquisitions of the biliary tree
  • Dynamic 3D fat-suppressed T1 (VIBE/LAVA) pre-contrast and arterial, portal venous, and delayed phases after 0.1 mmol/kg gadolinium
  • Hepatobiliary phase at 20 minutes when using gadoxetate for lesion characterization
  • Slice thickness 3-5 mm; timing arterial phase by bolus tracking or test bolus

Systematic Review

  • Assess overall liver morphology, signal, fat/iron content, and surface contour
  • Characterize each focal liver lesion across all sequences and dynamic phases
  • Trace the intra- and extrahepatic biliary tree and pancreatic duct on MRCP
  • Evaluate the pancreas for masses, ductal dilatation, and parenchymal signal
  • Assess both kidneys for masses, complex cysts, and enhancement
  • Characterize the adrenals for signal drop-out on opposed-phase imaging
  • Review the spleen, bowel, mesentery, and vasculature (portal/hepatic/splenic veins)
  • Inspect lymph nodes, ascites, and the imaged lung bases and skeleton

Key Findings & Significance

  • Arterial hyperenhancement with washout and capsule in a cirrhotic liver indicates HCC (LI-RADS)
  • Progressive nodular discontinuous peripheral enhancement following blood pool indicates hemangioma
  • Central scar with hepatobiliary-phase iso/hyperintensity favors focal nodular hyperplasia
  • Signal loss on opposed-phase imaging indicates intracellular fat (adenoma or adrenal adenoma)
  • Biliary ductal dilatation to an abrupt cutoff suggests obstructing stone or stricture/tumor
  • Cystic pancreatic lesion communicating with a dilated main duct suggests IPMN
  • Restricted diffusion in a solid mass raises concern for malignancy

Differential Considerations

  • Arterial-enhancing liver lesion: HCC, FNH, adenoma, hypervascular metastasis, transient hepatic attenuation difference
  • Cystic liver lesion: simple cyst, biliary hamartoma, hydatid, abscess, biliary cystadenoma/carcinoma
  • Pancreatic mass: adenocarcinoma, neuroendocrine tumor, focal pancreatitis, metastasis
  • Pancreatic cyst: IPMN, mucinous cystic neoplasm, serous cystadenoma, pseudocyst
  • Renal mass: clear cell/papillary RCC, oncocytoma, angiomyolipoma (fat-containing), complex cyst
  • Adrenal mass: adenoma (signal drop-out), pheochromocytoma, metastasis, myelolipoma, carcinoma

Pearls & Pitfalls

  • Chemical-shift signal drop-out reliably indicates microscopic fat (adenoma, adrenal adenoma, HCC)
  • Gadoxetate hepatobiliary phase distinguishes FNH (retains) from adenoma/metastasis (does not)
  • Transient severe motion during gadoxetate arterial phase can mimic or obscure lesions
  • Correlate DWI with ADC to avoid T2 shine-through misinterpretation
  • MRCP overestimates strictures if flow/pulsation artifact is present; use multiple projections
  • Do not mistake pseudolesions (perfusion changes, focal fat/sparing) for true lesions
  • Iron deposition lowers signal on in-phase relative to opposed-phase (reverse of fat)

Structured Report

  • State indication, technique, contrast agent/dose, and comparison studies
  • Report liver size, fat/iron content, and characterize each focal lesion with dynamic behavior
  • Apply LI-RADS categorization for at-risk patients
  • Describe biliary and pancreatic ductal caliber and any obstructing lesion
  • Report renal, adrenal, splenic, nodal, and vascular findings
  • Impression: specific characterization or ranked differential with management recommendation
  • Recommend biopsy, follow-up interval, or MDT referral as appropriate

References

  • ACR LI-RADS v2018 for HCC characterization
  • ACR Appropriateness Criteria: liver lesion characterization; suspected pancreatic disease
  • ESGAR/European consensus guidelines on pancreatic cystic neoplasms
  • RadioGraphics reviews on chemical-shift imaging and hepatobiliary contrast agents
  • Fujita/standard abdominal MRI protocols; ACR-SAR MRCP practice parameters

Educational clinical decision support only. Protocols vary by institution and equipment; always confirm with a qualified radiologist and local guidelines before clinical use.